Abstract: Objective To understand the non-alcoholic fatty liver disease ( NAFLD ) and its influencing factors in HIV/AIDS patients receiving antiretroviral therapy ( ART ), and to provide reference for the prevention and treatment of NAFLD in HIV/AIDS patients. Methods A total of 76 HIV/AIDS patients who were treated with ART in the Third People′s Hospital of Hebi City from October 2023 to April 2024 were selected as the research objects. Relevant data were collected and statistically analyzed. Results The proportion of NAFLD in 76 HIV/AIDS patients was 53.95%(41/76). The proportion of BMI ≥ 24 kg/m² (82.9%), the proportion of taking EFV regimen and ≥ 60 months(51.2%), the proportion of abnormal TG (73.2%), the proportion of abnormal blood lipid index ( 75.6 % ), the proportion of abnormal blood glucose ( 61.0% ) and body fat content ( 29.51% ± 4.98% ) in patients with NAFLD were higher than those in patients without NAFLD ( 37.1%, 22.9%, 37.1%, 51.4%, 31.4% and 24.83%± 6.14%, respectively ). The difference was statistically significant (P<0.05). Multivariate logistic regression analysis showed that BMI≥24 kg/m², taking EFV regimen and ≥ 60 months and abnormal TG may be influencing factors of NAFLD, and the difference were statistically significant (P<0.05). Conclusion The proportion of NAFLD in HIV / AIDS patients receiving ART is high. BMI ≥ 24 kg/m², taking EFV regimen and ≥ 60 months, and abnormal TG were influencing factors of NAFLD.

Key words: HIV/AIDS, Non-alcoholic fatty liver disease, Influencing factor